Atlas Trials

Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases

Clinical trial NCT07413952 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07413952
Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
NSCLC
Start date
2026-04-01
Primary completion
2027-12-31
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.